Heidelberg University Hospital, Centre for Infectious Diseases, Parasitology Unit

Key figures

• Research on pathogen/host interactions using techniques from the field of cell and molecular biology with immunology
• developed the first genetically defined live-attenuated parasites (GAP) to be used as an experimental whole-organism vaccine to sterily protect from malaria infection
• currently refining the GAP vaccine by either simplifying the administration or by a more feasible vaccination approach for people in endemic settings
• As mentor, founder and former shareholder of MalVa company Dr. Mueller advices the R&D activities centered around the development of a next-generation multicomponent anti-infective malaria vaccine

We offer

• Long-standing expertise in infectious diseases in particular vaccine design for malaria
• Antigen discovery technologies to identify novel vaccine candidates
• Expertise in pre-clinical testing of vaccine formulations and animal challenge models
• Murine malaria infection model available for both drug and vaccine formulation testing